Evaxion A/S
EVAXNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for EVAX. That does not mean none is planned.
Get an email about EVAX's next catalysts
Track Evaxion A/S (EVAX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
3 upcoming events in our data (conference, earnings).See the timeline
3 upcoming, 0 past
Conference — EVX-01
For advanced melanoma. Evaxion will present new biomarker data from its phase 2 trial of personalized cancer vaccine EVX-01 plus pembrolizumab in advanced melanoma at SITC 2026 in Phoenix (Nov 4-8), via oral and poster sessions. Previously reported results include a 75% ORR (12 of 16 patients) at two years, with responses sustained at three years.
SourceEVAX Earnings Report
FQ end Sep/2026 | Call: bmo
Conference Presentation - EVX-01
For advanced melanoma. Evaxion will present new biomarker data from its phase 2 trial of personalized cancer vaccine EVX-01 plus pembrolizumab in advanced melanoma at SITC 2026 in Phoenix (Nov 4-8), via oral and poster sessions. Previously reported results include a 75% ORR (12 of 16 patients) at two years, with responses sustained at three years.
SourceMarket Overview
Stock performance and key metrics
No drugs found in this phase.
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
When is Evaxion A/S's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Evaxion A/S (EVAX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track EVAX biotech catalysts?→
Add EVAX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Evaxion A/S's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.